Helix, a leader in population genomics, is launching new datasets to aid life science companies in developing precision medicine therapies. These datasets, created through collaborations with various health systems, provide researchers with a valuable resource for drug discovery and development across multiple disease areas by combining longitudinal clinical data with genomic information.
The datasets encompass extensive medical records and genetic data covering areas such as cardiovascular diseases, immunological and inflammatory conditions, and metabolic disorders. Helix's approach involves "precision cohorts," carefully curated groups of patients with specific characteristics, combining clinical data and genetic information from Helix’s Exome+® sequencing technology. This comprehensive data set includes over 125,000 consented patients in the US, facilitating targeted research.
Regular updates enhance the datasets, ensuring researchers have access to the latest clinical information from electronic health records (EHRs). For example, the Cardiometabolic cohort includes data for over 50,000 patients with cardiovascular disease, linking clinical data to exome sequencing data. This allows researchers to identify genetic variations influencing disease risk and treatment response.
Helix's clinico-genomic cohorts help researchers understand genetic factors in disease progression, validate therapeutic candidates, and rapidly identify targeted patient populations based on genetic and phenotypic criteria.
Click here to read the original news story.